Our Pricing

What Is Mounjaro and How Can Caterham Residents Access It?

Published: 3 October 2026

Mounjaro Caterham residents can now access through Cured Pharmacy, a fully UK-registered online service offering tirzepatide weight loss injections from £124.99 with free prescriber consultations. As a GPhC-registered pharmacy (9012511), we provide Caterham patients with genuine MHRA-licensed Mounjaro delivered discreetly to your door, supported by our superintendent pharmacist Tarun Kumar (GPhC 2233073). Clinical trials demonstrate that Mounjaro may help eligible patients achieve significant weight reduction when combined with lifestyle modifications, subject to prescriber approval following online assessment [1].

How Mounjaro Caterham Services Work at Cured Pharmacy

Accessing Mounjaro Caterham through our online pharmacy involves a streamlined three-step process designed for convenience and clinical safety. First, Caterham residents complete a confidential online consultation (under 3 minutes) where our UK-registered prescribers review your medical history, current medications, and weight loss goals. This assessment ensures Mounjaro is clinically appropriate for your individual circumstances, as tirzepatide is a prescription-only medicine requiring professional evaluation before dispensing [2].

Once approved, your Mounjaro prescription is fulfilled by our GPhC-registered pharmacy team and dispatched in 100% discreet packaging directly to your Caterham address. We guarantee transparent upfront pricing at £124.99 for Mounjaro, with no hidden consultation fees. New patients receive £20 off their first order using code Weightlossnew, making your initial supply more accessible. All medications are sourced exclusively from UK-licensed wholesalers, ensuring authenticity and regulatory compliance with MHRA standards throughout the supply chain.

Mounjaro Caterham Pricing and Dosage Options

Mounjaro Caterham pricing at Cured Pharmacy starts from £124.99, reflecting our commitment to competitive UK pricing without compromising pharmaceutical quality. Tirzepatide is supplied in pre-filled KwikPen injectors containing four weekly doses, with dosage strengths ranging from 2.5mg (starter dose) through 5mg, 7.5mg, 10mg, 12.5mg, to the maximum 15mg maintenance dose. Your prescriber determines the appropriate titration schedule based on your response and tolerability, typically increasing every four weeks to optimise efficacy whilst minimising gastrointestinal side effects [3].

The structured dose escalation protocol used with Mounjaro Caterham prescriptions mirrors the SURPASS clinical trial methodology, where gradual increases allowed participants' bodies to adapt to tirzepatide's dual GIP/GLP-1 receptor agonist effects. This approach significantly reduces the incidence of nausea and vomiting compared to starting at higher doses immediately. Our pricing remains consistent across all strengths, ensuring cost predictability as you progress through your weight loss journey under prescriber supervision.

Understanding Mounjaro's Dual Mechanism

Mounjaro Caterham patients benefit from tirzepatide's unique dual-action mechanism, which activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonism enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways. In the SURPASS-1 trial, participants receiving tirzepatide 15mg achieved an average weight reduction of 22.5% over 72 weeks, demonstrating superior efficacy compared to single-receptor agonists [1].

Clinical Evidence Supporting Mounjaro Caterham Prescriptions

The decision to prescribe Mounjaro Caterham patients is grounded in robust clinical trial data from the SURPASS programme, which enrolled over 6,000 participants with obesity or overweight plus weight-related comorbidities. SURPASS-2 directly compared tirzepatide against semaglutide 1mg, showing that Mounjaro 10mg and 15mg doses produced significantly greater weight loss (average 12.4kg and 14.0kg respectively) compared to semaglutide's 5.7kg over 40 weeks [4]. These findings position tirzepatide as the most effective pharmacological weight loss intervention currently licensed in the UK.

For Mounjaro Caterham prescribing decisions, our clinical team also considers the SURMOUNT-1 trial, which specifically studied tirzepatide in patients without diabetes. Participants achieved average weight reductions of 15.0%, 19.5%, and 20.9% with 5mg, 10mg, and 15mg doses respectively over 72 weeks, compared to 3.1% with placebo [5]. Importantly, 89% of participants receiving the highest dose achieved at least 5% weight loss (the threshold for clinically meaningful benefit), whilst 57% achieved ≥20% reduction. These outcomes inform our prescribers' assessments when evaluating Caterham patients' suitability for treatment.

Safety Profile and Side Effect Management

Mounjaro Caterham prescriptions come with comprehensive safety guidance, as tirzepatide's most common side effects involve the gastrointestinal system. Clinical trials reported nausea (12-22%), diarrhoea (13-16%), vomiting (6-10%), and constipation (6-11%) across dose ranges, typically most pronounced during dose escalation phases and diminishing with continued use [3]. Our prescribers provide Caterham patients with practical management strategies including eating smaller meals, avoiding high-fat foods, and maintaining adequate hydration to minimise these effects.

Mounjaro Caterham Delivery and Convenience Benefits

Cured Pharmacy's Mounjaro Caterham delivery service eliminates the need for in-person pharmacy visits, providing particular convenience for patients with mobility limitations or busy schedules. Once your prescription is approved, we dispatch your medication via Royal Mail or courier services with full tracking, typically arriving within 1-2 working days to Caterham addresses. Our discreet packaging contains no external branding or product information, respecting your privacy throughout the delivery process.

For ongoing Mounjaro Caterham treatment, we offer subscription services that automatically schedule your next supply based on your dosing regimen, with prescriber review at appropriate intervals. This ensures treatment continuity without the risk of running out between doses, which is particularly important given tirzepatide's weekly injection schedule. Our pharmacy team proactively contacts you before each dispatch to confirm your address and answer any questions about administration technique or side effect management, providing the personalised support expected from a superintendent pharmacist-led service.

Who Can Access Mounjaro Caterham Through Online Prescribing

Mounjaro Caterham eligibility follows MHRA licensing criteria and NICE guidance for weight management medications. Generally, tirzepatide is prescribed for adults with a body mass index (BMI) of 30 kg/m² or above, or BMI 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Our online consultation specifically assesses these criteria alongside contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease [6].

Caterham patients with type 2 diabetes may be particularly suitable candidates for Mounjaro Caterham prescriptions, as tirzepatide provides dual benefits of glycaemic control and weight reduction. The SURPASS-2 trial demonstrated HbA1c reductions of 2.01-2.46% alongside the substantial weight loss previously mentioned [4]. However, our prescribers carefully evaluate medication interactions, particularly with insulin or sulfonylureas which may require dose adjustments to prevent hypoglycaemia when combined with tirzepatide's glucose-lowering effects.

Contraindications and Precautions

Certain Mounjaro Caterham applications will be declined based on absolute contraindications. Pregnancy and breastfeeding represent clear exclusions, as tirzepatide's effects on foetal development and infant exposure remain inadequately studied. Women of childbearing potential should use reliable contraception during treatment and discontinue Mounjaro at least two months before planned conception. Additionally, patients with severe renal impairment (eGFR <30 mL/min/1.73m²) require cautious evaluation, as gastrointestinal side effects may lead to dehydration and acute kidney injury in this vulnerable population [6].

Starting Your Mounjaro Caterham Journey with Cured Pharmacy

Beginning Mounjaro Caterham treatment through our pharmacy involves completing the online consultation accessible via our website's weight loss assessment portal. The questionnaire covers your medical history, current medications, previous weight loss attempts, and specific health conditions that may influence prescribing decisions. Our UK-registered prescribers typically review submissions within 24 hours, with most Caterham patients receiving approval decisions the same working day, subject to providing complete and accurate information.

Upon approval, your first Mounjaro Caterham prescription will be for the 2.5mg starter dose, taken as a single weekly subcutaneous injection. Our pharmacy team provides comprehensive administration instructions including injection site rotation (abdomen, thigh, or upper arm), proper pen technique, and sharps disposal guidance compliant with Caterham local authority regulations. Remember to apply your Weightlossnew discount code at checkout to receive £20 off this initial supply, reducing your starting cost whilst you evaluate tirzepatide's tolerability and early efficacy during the first month of treatment.

Ongoing Monitoring and Prescriber Support

Mounjaro Caterham patients receive continuous clinical oversight through our online platform, where you can report side effects, request dose adjustments, or seek advice between scheduled reviews. Our prescribers conduct formal reassessments every 12 weeks to evaluate weight loss progress, tolerability, and continued appropriateness of treatment. If you achieve less than 5% weight loss after 16 weeks at therapeutic doses, our clinical team will discuss alternative strategies, as NICE guidance suggests discontinuation when adequate response is not achieved [7]. This evidence-based approach ensures Mounjaro Caterham prescriptions remain clinically justified throughout your treatment course.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 3 October 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA UK Public Assessment Report. [accessed 3 October 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583-598. [accessed 3 October 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10303), 1001-1014. [accessed 3 October 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 3 October 2026]
6. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. Summary of Product Characteristics. [accessed 3 October 2026]
7. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [ID6209]: Final scope. NICE Technology Appraisal Guidance. [accessed 3 October 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 3 October 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 3 October 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 3 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.